NCT04739566 2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT02143050 2023-11-18
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
Phase 1/2 Withdrawn
NCT05299580 2023-09-14
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
Phase 2 Withdrawn
NCT05677373 2023-08-18
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT02300935 2019-05-30
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
SCRI Development Innovations, LLC
Phase 1 Withdrawn
NCT02915666 2018-05-15
A Clinical Trial of Patients With Melanoma
University of Texas Southwestern Medical Center
Phase 1 Withdrawn
NCT02342600 2017-10-12
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
Sarcoma Alliance for Research through Collaboration
Phase 2 Withdrawn
NCT02140840 2016-04-07
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib
University of Arkansas
Phase 2 Withdrawn
NCT02357732 2015-12-11
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
University of Pittsburgh
Phase 1 Withdrawn